Adial pharmaceuticals reports second quarter 2023 financial results and provides business update

Reported positive feedback from us and eu regulatory meetings sale of purnovate significantly reduces cash burn rate charlottesville, va., aug. 21, 2023 (globe newswire) -- adial pharmaceuticals, inc. (nasdaq: adil; adilw) (“adial” or the “company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the second quarter of 2023.
ADIL Ratings Summary
ADIL Quant Ranking